预约演示
Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy
引进/卖出临床2期临床3期临床申请
Prothena’s investigational new drug application for PRX019 was cleared by the FDA in December 2023. Now, Bristol Myers Squibb is paying out $80 million for exclusive global rights.
ProthenaMyers Squibb is again dipping into the well PRX019rapies being developFDAby Prothena, this time fBristol Myers Squibbnse to a neurodegenerative candidate that is about to slide into human testing.
Bristol Myers Squibbtional new drug (IND) application for PRX019 was cleared by the Prothenaecember 2023, and, now, BMS is paying out $80 million for exclusive global rights. The therapy is aimed at an undisclosed target, and a trial is expected to get underway by the end of this year, according to a Tuesday evening press release.
This is the second clinical proProthenaProthenacome out of the Prothena-BMS collaboration after the Big Pharma paid out $55 million for a worldwide license to clinical-phase Alzheimer’s disease candidate PRX005 in July 2023. BMS previously paid $80 million to Prothena for an initial opt-in on U.S. rights to PRX005 in 2021.
Prothena has additional deals with Novoamyotrophic lateral sclerosis ATTR amyloidosis TDP-43ate and Roche, where the companies are developing prasinezumab for Parkinson’s disease, also in phase 2.
Prothena along in the pipeline is bNovo Nordiskhich Prothena is develATTR amyloidosisAL amyloidosis Rochease 3.prasinezumabParkinson’s disease
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。